Business Insider19d
Compass Pathways announces published study on psilocybin in depression
Compass Pathways (CMPS) announced the publication of results from the COMP004 study, an observational 52-week follow-up from the Phase 2 COMP001 and COMP003 trials of COMP360 psilocybin treatment ...
Morningstar11d
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Screening closed for all sites and final participants being scheduled for dosing On track for top-line 6-week primary endpoint results in late Q2 Compass Pathways plc (Nasdaq: CMPS), a ...
Morningstar26d
Compass Pathways to Participate in Stifel Virtual CNS Forum
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at ...
Business Insider1mon
Compass Pathways price target lowered to $45 from $60 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Compass Pathways (CMPS) to $45 from $60 and keeps a Buy rating on the shares. The firm says the company’s capital raise in January was more ...